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Tumor epithelial cells within a tumor coexist with a complex micro-
environment in which a variety of interactions between its various
components determine the behavior of the primary tumors. Can-
cer-associated fibroblasts (CAF) and M2 macrophages, character-
ized by high expression of different markers, including a-SMA,
FSP1 and FAP, or CD163 and DCSIGN, respectively, are involved in
the malignancy of different tumors. In the present study, expres-
sion of the above markers in CAF and M2 macrophages was ana-
lyzed using RT-PCR and immunohistochemistry in the normal
mucosa and tumor tissue from a cohort of 289 colorectal cancer
patients. Expression of CAF and M2 markers is associated with the
clinical outcome of colorectal cancer patients. Moreover, the com-
bination of CAF and M2 markers identifies three groups of patients
with clear differences in the progression of the disease. This com-
bined variable could be a decisive factor in the survival of
advanced-stage patients. Taken together, these analyses demon-
strate the prognostic involvement of interrelationships between
DCSIGN, CD163, a-SMA, FSP1 and FAP markers in the survival of
colon cancer patients. (Cancer Sci 2013; 104: 437–444)
C olorectal cancer (CC) is one of the most common diseasesin Western populations.(1) Currently, in clinical practice,
although various biological and molecular markers have been
suggested as useful tools for determining treatment and prog-
nosis, the parameter most closely linked to the survival of
patients is the stage of the disease.
Molecular characteristics relating to prognosis are usually
linked to features of carcinoma cells. Thus, the level of carci-
noembryonic antigen, which today is the most informative
serum marker, depends on its expression in carcinoma cells.(2)
However, tumor epithelial cells within a tumor coexist with
a complex microenvironment or stroma.(3) In this complex sce-
nario, a variety of interactions between its various components
takes place. These might determine a series of events, such as
tumor cell proliferation, metastatic potential and location of
metastases.(4,5)
Fibroblasts are one of the most active cell types of the
stroma.(6) Fibroblasts are present in the stroma of normal tis-
sues, where they perform tissue repair functions under certain
physiological conditions, and in the stroma of tumors, in which
they might represent the main component.(7) They have been
given various names: tumor-associated fibroblasts, carcinoma-
associated fibroblasts (CAF) or myofibroblasts.(8) In this state
of permanent activation, fibroblasts can promote tumor growth
and tumor progression, favoring a variety of tumor-specific
mechanisms,(9) which can influence the behavior of tumors
and the prognosis of patients.(10) These activated fibroblasts
can be characterized molecularly by several markers that
should be expressed by the fibroblasts in their activated state.
Some of the most common CAF markers are a-smooth muscle
actin (a-SMA), fibroblast-specific protein 1 (FSP1 or S100A4)
and fibroblast activation protein (FAP).(6,7) It has been sug-
gested that individually these markers could identify specific
subpopulations of fibroblasts and that it would be more appro-
priate to use several markers to select the largest possible
population of tumor fibroblasts.(11)
Inflammatory states can be associated with a risk for the
development and progression of cancers.(12) Tumor-associated
macrophages can be found in the tumor in two phenotypi-
cally different populations: (i) M1 macrophages that will
develop an antitumor response by activating the immune
system and producing reactive oxygen species, nitric oxide
and tumor necrosis factor; and (ii) M2 macrophages that
will perform immunosuppressive functions and tumor promo-
tion,(13) as well as implementing the metastatic process by
promoting angiogenesis and degradation of the extracellular
matrix.(14) This binary balance between M1 ⁄M2 cells has
been verified using gene profiles, which support this pheno-
typic and functional change.(15) The difference between M1
and M2 macrophages has been defined based on the cyto-
kine production of IL-10 and IL-4 ⁄ IL-13, respectively.(16–18)
In addition, different markers are used to distinguish M1
and M2 macrophages. Thus, expression of CD163, or the
most recently described, DCSIGN, are characteristics of M2
macrophages.(16,17) Despite the macrophage classification
schemes, little is known about the complexity of the micro-
environment populations of macrophages and their associa-
tions with clinical cancer progression.
Together with M2 macrophages, and as previously stated
above, CAF are a large component of the stroma and generally
tumor promoting. In this scenario, assessment of association
between M2 plus CAF markers and survival of colon cancer
patients is required. Results with prognostic implications, indi-
vidually using some of the above markers, have been
reported.(19–22) The present study evaluates activation of fibro-
blasts and macrophages together using the analysis of CAF
markers (a-SMA, FSP1 and FAP) and M2 macrophages
(CD163 and DC-SIGN) to establish their relationship with
clinical parameters and patient survival.
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Materials and Methods
Patients and samples. The present study is based on a con-
secutive series of 289 patients undergoing surgery for CC
between January 2002 and December 2006. Informed written
consent was obtained from all participants, as approved by the
Research Ethics Board of Puerta de Hierro Majadahonda Uni-
versity Hospital. Tumor and normal colon mucosa (taken at
least 3 cm from the outer tumor margin) were obtained imme-
diately after surgery, snap-frozen in liquid nitrogen and stored
at 80°C until processing.
RNA extraction and real-time PCR. RNA extraction, target
gene mRNA quantification and synthesis of cDNA were per-
formed as previously described.(23)
An arbitrary value (0.01), corresponding to half the mini-
mum value detected in the series, was assigned to the normal
or tumor samples in which target gene expression was not
detected, but expression of housekeeping was observed.
Patients with normal or tumor samples without detection of
housekeeping were excluded.
Immunohistochemistry analysis and antibodies. Anti-DC-
SIGN antibody [5D7] (Abcam, Cambridge, UK), anti-human
CD163 (clone 10D6; Novocastra, Barcelona, Spain), anti-alpha
smooth muscle actin antibody [1A4] (Abcam), anti-human
S100A4 (DAKO, Glostrup, Denmark), peptide-affinity purified
polyclonal antibody to fibroblast activation protein (FAP) alpha
(Imgenex, San Diego, CA, USA) were used for cell immuno-
staining.
Procedures were performed as previously described.(24)
Immunohistochemistry data were evaluated as “low” or
“high” expression, regarding the rate of positive cells for each
sample and each marker. The analysis was evaluated by two
independent pathologists.
Clinical-pathological characteristics, follow up and treatment of
patients. The parameters obtained from the medical records of
289 patients were age, sex, tumor location, lymph node metasta-
ses, pathological stage (tumor–node–metastases classification),
tumor histological grade, presence of polyposis in the surgical
specimen and the presence of vascular invasion in tumors.
Colon cancer patients did not receive neo-adjuvant chemo-
therapy. Patients with rectal carcinoma who had received
preoperative treatment with chemotherapy and radiotherapy
or radiotherapy alone were excluded because of the difficulty
of finding a suitable tumor for determining gene expression in
these patients’ surgical samples. Adjuvant treatment based on
oxaliplatin (FOLFOX6, leucovorin 400 mg ⁄m2 i.v. on day 1 as
a 2-h infusion, followed by 5-fluorouracil bolus of 400 mg ⁄m2
i.v. on day 1, followed by 2400 mg ⁄m2 i.v. 46-h infusion and
oxaliplatin 100 mg ⁄m2 i.v. as a 2-h infusion on day 1) was
administered to patients when clinically indicated and without
medical contraindications who gave their written informed
consent.(25) Radiotherapy was also administered in rectal tumor
cases.
Clinical follow up after surgery and diagnosis was based on
periodic visits and clinical, biochemical and imaging tech-
niques. Ultrasonic study was performed when liver function
was impaired. Overall survival (OS) and disease-free survival
(DFS) were defined as the period of time from diagnosis to
death and the interval between diagnosis and first recurrence,
respectively.
Statistical analysis. Spearman correlation was used to analyze
correlation among different target genes. Protein and mRNA
data association were contrasted using t-test following evalua-
tion of equality of variance or not with Levene’s test. Two-
tailed P-values  0.05 were considered statistically different.
mRNA expression data of a-SMA, FSP1, FAP, CD163 and
DCSIGN were divided by tertiles (33% and 66%) to get
three groups of patients and develop the statistical analysis of
association with clinical-pathological parameters (v2 test) or
OS and DFS (tests were carried out as previously
described(23)). In this way, patients between 0% and 33% fitted
into the lower mRNA data expression of the target gene and
were included in the “low expression group,” patients between
33% and 66% were in the “medium expression group” and
patients between 66% and 100% were in the “high expression
group.”
Results
Descriptive data of patient series and CAF and M2 macrophage
markers. A large cohort of 289 tumor and normal counterpart
tissue samples from 289 CC patients was studied. The patients
included 179 males and 110 females. Eighteen cases were clas-
sified as pathological stage I, 157 were stage II, 100 were
stage III and 14 stage IV. The series was followed for a mean
of 5 years (range of patient follow ups: 1–187 months). Of
275 patients with known data, 86 recurrences were recorded
during this period. The number of exitus observed during the
period was 88. The number of patients in which detection of
the target gene was possible and generic data of each gene
mRNA quantification is detailed in Table 1.
Spearman’s test revealed a direct correlation between macro-
phage and CAF markers (Table 2). In parallel, correlation
among CAF and M2 macrophage markers was observed,
excluding FAP and DCSING (Table 2).
Sixty tumor samples and the normal counterpart were ana-
lyzed for DCSIGN, CD163, a-SMA, FSP1 and FAP stromal
protein expression. Stromal target protein expression was eval-
uated as low or high levels and its association with mRNA
expression levels was analyzed (Fig. 1). Statistical association
was observed between mRNA expression levels and protein
levels of FSP1 and FAP. In addition, a clear trend toward sta-
tistical association was found between protein and mRNA
expression levels of DCSIGN, CD163 and a-SMA (Fig. 1B).
CAF and M2 markers are associated with patients’ clinical char-
acteristics. Statistical association between high mRNA levels
Table 1. Expression data of CAF and M2 macrophage markers
studied in colorectal cancer patients
DCSIGN CD163 a-SMA FSP1 FAP
n 239 235 270 264 208
Median 0.31 1.18 0.52 1.90 14.48
Minimum <0.01 <0.01 <0.01 <0.01 <0.01
Maximum 62.34 2227.07 522.47 642.67 299093.11
33 percentile 0.16 0.39 0.20 0.76 3.90
66 percentile 0.58 2.72 1.24 3.97 60.95
CAF, cancer-associated fibroblast; FAP, fibroblast activation protein;
FSP1, fibroblast-specific protein 1; SMA, smooth muscle actin.
Table 2. Correlation between the expression levels of M2
macrophage and CAF markers in colorectal cancer patients
CD163 a-SMA FSP1 FAP
DCSIGN r = 0.321;
P < 0.001
r = 0.381;
P < 0.001
r = 0.181;
P = 0.007
r = 0.008;
P = 0.916
CD163 r = 0.460;
P < 0.001
r = 0.257;
P < 0.001
r = 0.419;
P < 0.001
a-SMA r = 0.314;
P < 0.001
r = 0.333;
P < 0.001
FSP1 r = 0.445;
P < 0.001
CAF, cancer-associated fibroblast; FAP, fibroblast activation protein;
FSP1, fibroblast-specific protein 1; SMA, smooth muscle actin.
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of CD163, a-SMA and FSP-1 and recurrence was observed
(P = 0.023, P = 0.028 and P = 0.012, respectively), while
only a trend toward statistical association was found for FAP
(P = 0.083). In addition, CD163 was also statistically associ-
ated with exitus (P = 0.029) and a trend linking a-SMA, FSP1
and FAP with exitus was found (P = 0.154, P = 0.067 and
P = 0.143, respectively).
No relationship was found between the stromal markers ana-
lyzed and other clinical-pathological variables, including the
sex of patients, tumor location, histological degree, vascular
invasion, polyposis, lymph node metastases and pathological
stage (data not shown).
CAF and M2 macrophage markers are associated with DFS and
OS. Statistical association between DFS and the mRNA
expression levels of a-SMA and FSP-1, CAF markers and
CD163, and the M2 macrophage marker was observed (Fig.
S1A,B). There was also a trend between FAP expression levels
and DFS (Fig. S1A). Kaplan–Meier analysis revealed similar
behavior of different gene expression data tertiles of each
gene. Therefore, to simplify the analysis, those tertiles were
grouped according to mathematical behavior as “high” and
“low” expression of the target gene (Fig. S1). The new analy-
sis with these two categories improves the prognostic value for
CD163, a-SMA, FSP-1 and FAP (Fig. 2).
CD163 mRNA expression levels were statistically associated
with OS in CC patients (Fig. 3A). There was a statistical asso-
ciation between the expression levels of FSP-1 and OS
(Fig. 3C). Patients whose tumors revealed high expression
levels of a-SMA or FAP showed a trend towards shorter OS
(Fig. 3B,D).
Together, these results indicate the clinical meaning of
a-SMA, FSP1 and FAP, CAF markers and CD163, a M2
macrophage marker, as all of them showed a clear association
with cancer patients’ survival.
No association between DCSIGN, and DFS or OS was
found. The dichotomization of the variable, based on mathe-
matical behavior, did not show any association either (Fig.
S1B,C). However, this variable was included in further analy-
sis as Cox analysis demonstrated its usefulness, also indicating
its involvement in clinical cancer prognosis.
Combination of CAF and M2 macrophage markers predicts DFS
and OS. To study the possible additive effect of different mar-
kers expression, the patients were classified in different groups
according to the number of CAF and M2 markers highly
expressed. Thus, patients were first classified based on the
expression of zero, one, two or three CAF markers and expres-
sion of zero, one or two M2 markers. Then, association with
DFS was established (P = 0.009 and P = 0.030, respectively).
Next, to dichotomize the analysis, and based on similar
mathematical behavior, patients with zero, one or two CAF
markers were grouped as “low-rate CAF” versus those with
three markers of expression, “high-rate CAF.” Likewise, the
“low-rate M2” group included no expression of any marker
and the “high-rate M2” group had expression of one or two
M2 macrophage markers. Previously observed correlation
between DFS or OS was confirmed (CAF markers: P = 0.004
(A)
(B)
Fig. 1. mRNA quantitative expression versus immunohistochemistry. (A) DCSIGN, CD163 M2, a-smooth muscle actin (a-SMA), fibroblast-specific
protein 1 (FSP1) and fibroblast activation protein (FAP) immunohistochemistry. Representative pictures of high and low protein expression levels
of DCSIGN, CD163 M2 macrophage and a-SMA, FSP1 and FAP cancer-associated fibroblast (CAF) markers in human tumor samples. Arrows indi-
cate positive cells. Original magnification, 920. (B) Association between protein and mRNA expression levels. Statistical association between pro-
tein and mRNA expression levels of FSP1 and FAP, CAF markers. In addition, a clear trend toward statistical association is observed between
protein and mRNA expression levels of DCSIGN and CD163, M2 macrophage markers and the a-SMA, CAF marker. Bar charts show the average
(confidence interval) of mRNA expression levels of each gene in the low and high protein expression groups.
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and P = 0.038; M2 markers: P = 0.009 and P = 0.015, for
DFS and OS, respectively).
Finally, expression of CAF and M2 markers were combined
and patients classified as “basal” (low-rate CAF and M2 mark-
ers), “middle” (low-rate CAF markers and high-rate M2 mark-
ers or vice versa) or “solid stromal expression” (high-rate CAF
and M2 markers). This classification was then used for further
studies. Statistical analysis showed that the rate of CAF–M2
markers also correlated with DFS and OS (Fig. 4A,B, respec-
tively).
In parallel, CAF–M2 markers, together with vascular inva-
sion, histological degree and pathological stage were deter-
mined as independent prognostic variables for DFS (Table 3)
and CAF–M2 markers, vascular invasion and pathological
stage were for OS (Table 3).
CAF–M2 markers’ association with DFS and OS according to
the pathological stage localization of the tumors. The prognostic
value of CAF–M2 markers in different tumor stages was also
studied. The analysis showed that the expression levels of our
CAF–M2 markers correlated with DFS in early (P = 0.052)
and advanced (P = 0.050) stages (Fig. 4C). Nevertheless, OS
analysis showed that the studied markers tended to show a
prognosis value in stages III and IV (P = 0.069) (Fig. 4D), but
not in earlier stages (P = 0.596).
Because the results suggested that the studied markers
behave as a better predictive variable in the advanced stage for
OS, the multivariate models were rechecked stratifying the ser-
ies for stage status. This analysis confirmed that the studied
variable CAF–M2 markers interacts with the pathological
stage, giving a prognostic value for OS in patients in stage III
or IV (Table 4).
Finally, we were interested in determining whether the
CAF–M2 markers variable behaved differently regarding ana-
tomical tumor area. Survival analysis revealed clear differ-
ences in DFS and OS for patients with colon tumors only
(Fig. 4E,F, respectively). In contrast, involvement of the
CAF–M2 marker variable in the survival of patients with
rectal carcinomas was not observed.
Discussion
Cancer-associated fibroblasts contribute to a tumor-permissive
neighborhood and M2 macrophages display immunosuppres-
sive and tumor-promoting functions, including prometastatic
function by production of angiogenic and extracellular matrix
breakdown factors.(23) Although some steps involved in the
cross-talk between these cells are known, there is still a lot
that is not clear, but if clarified could lay the foundations for
the development of new treatment strategies that could be used
to control the disease.
Although some evidence individually supports our findings
on CAF markers in the prognosis of CC,(20–22) very little is
(A) (B)
(C) (D)
Fig. 2. Kaplan–Meier curves between expression levels of cancer-associated fibroblast (CAF) and M2 macrophage markers (individually) and
disease-free survival (DFS) in colorectal cancer patients. Association between CD163, a M2 macrophage marker (A), and a-smooth muscle actin
(a-SMA) (B), fibroblast-specific protein 1 (FSP1) (C) and fibroblast activation protein (FAP) (D) CAF markers with DFS. “Low expression” refers to a
low-expression tertile for a-SMA and low- and medium-expression tertiles for CD163, FSP1 and FAP.
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known about M2 markers. In fact, infiltration of tumor-associ-
ated macrophages correlates in many cancers with a bad prog-
nosis. However, it has also been reported that a greater
abundance of macrophages in CC correlates with a more
favorable prognosis.(26) These contradictory data could be clar-
ified with specific M1 and M2 markers. Thus, we observed
that mRNA expression levels of CAF expression markers are
related to poor DFS and OS, but that when the addition of M2
markers to survival analysis is taken into consideration, this
relationship is more robust. Moreover, multivariate analysis
clearly demonstrates that this variable, with both types of
markers, is an individual prognostic marker that is statistically
stronger than CAF markers or M2 markers individually.
Stromal gene expression profile assesses the difference
between pathological stages in gastrointestinal cancers or
between normal and tumor fibroblasts in colon cancer. How-
ever, these studies did not demonstrate prognostic involvement
of the stromal gene expression profile.(27,28) We think that our
results can be more easily translated into clinical practice,
therefore helping to identify patients with a worse prognosis.
Even more interesting is the interaction between the expression
of our five selected CAF and M2 markers and the pathological
stage. As multivariate analysis shows, the effect of our studied
markers is stronger in advanced stages for OS. Today, the
available therapies based on chemotherapy and biological tar-
geting strategies, administered as adjuvant treatment in stage
III or when the disease is metastatic, have increased both DFS
and OS. Thus, these longer survivals are a favorable event that
will permit us to see the positive relationship of our stromal
markers and patient survival in advanced stages. In this con-
text, it is possible that new therapies targeting microenviron-
ment components could help improve the medical treatment of
CC, especially those with a worse outcome.
The lack of association between our five studied CAF and
M2 markers and the prognosis in rectal cancer patients is
also interesting. First, these patients were the smallest group
in our cohort (16% of the total series) and a random effect
is possible. However, we could argue that rectal tumors
behave differently from colon tumors. The treatment for
rectal cancer is a modification of traditional colon cancer
treatment, mainly because of the addition of radiotherapy
combined with chemotherapy, administered preoperatively.
However, the rectal carcinomas in our series received the
treatment postoperatively, allowing us to obtain representa-
tive tumor samples for a correct molecular study. This could
indicate that radiotherapy in rectal carcinomas modifies the
behavior of the disease and, thus, the informative value of
the molecular markers studied. However, it is also possible
that in rectal carcinoma the stromal component has a differ-
ent biological significance, whereby fibroblasts and M2 mac-
rophages might play roles that are different from those
observed in colon carcinomas.
(A) (B)
(C) (D)
Fig. 3. Kaplan–Meier curves between expression levels of cancer-associated fibroblast (CAF) and M2 macrophage markers (individually) and
overall survival in colorectal cancer patients. Association of CD163, a M2 macrophage marker (A), and fibroblast-specific protein 1 (FSP1) (C), a
CAF marker, with overall survival. a-Smooth muscle actin (a-SMA) (B) and fibroblast activation protein (FAP) (D) expression levels, CAF markers,
showed a trend towards an association with overall survival.
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The clinical meaning of the present study is indicated by the
observation of the prognostic involvement of DCSIGN and
CD163, M2 macrophage markers, a-SMA, FSP1 and FAP
CAF markers, as well as their interrelationship in colon cancer
patients’ survival, particularly in those at advanced stages.
Knowledge of the real involvement of these factors in the
development of the disease encourages the search for new
therapies that would target the stromal component of colorectal
(A) (B)
(C) (D)
(E) (F)
Fig. 4. (A,B) Kaplan–Meier curves between the expression levels of cancer-associated fibroblast (CAF) plus M2 macrophage markers and colorec-
tal cancer (CC) patient survival. Association between the variable CAF plus M2 macrophage markers taken together and disease-free survival
(DFS) (A) or overall survival (OS) (B). “Basal stromal expression” includes the CAF and M2 low-rate markers variable. “Middle stromal expression”
comprises CAF high-rate markers and M2 low-rate markers or vice versa. “Solid stromal expression” contains CAF and M2 high-rate markers.
(C,D) Kaplan–Meier curves between the expression levels of CAF plus M2 macrophage markers and survival for the pathological stage in colorec-
tal cancer (CC) patients. Association between the variable of CAF plus M2 macrophage markers taken together and DFS in patients with
advanced pathological stages (C). A clear trend was observed in advanced pathological stages between CAF plus M2 markers and OS (D). (E,F)
Kaplan–Meier curves between the expression levels of CAF plus M2 macrophage markers and survival in relation to tumor location in CC
patients. A clear association was observed between CAF plus M2 macrophage markers and DFS in colon cancer patients (E). Similar results were
found for OS; the association was observed in colon cancer patients (F).
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and other cancers and offer a synergistic effect with the
current systemic therapies.
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3.319 1.555–7.085 0.002
Overall
survival
Vascular
invasion
Yes vs No 1.649 0.979–2.778 0.060
Pathological
stage
III + IV vs
I + II
5.001 2.824–8.856 <0.001
CAF–M2 0.044
Middle vs
Basal
stromal
expression
1.564 0.792–3.086 0.197
Solid vs
stromal
expression
2.445 1.185–5.045 0.016
CI, confidence interval; HR, hazard ratio.
Table 4. Statistical interaction between CAF–M2 variable and tumor
pathological stage regarding overall survival predictive outcome
value in colorectal cancer patients
Variable Category HR 95% CI P-value
Overall
survival
Vascular
invasion
Yes vs No 1.743 1.024–2.966 0.041
Pathological
stage
III + IV vs
I + II
2.818 1.128–7.040 0.027
CAF–M2 *
Pathological
stage
0.035
Stage *
Middle vs
Basal
stromal
expression
1.574 0.675–3.669 0.294
Stage * Solid
vs Basal
stromal
expression
2.951 1.204–7.232 0.018
CI, confidence interval; HR, hazard ratio.
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Fig. S1. Kaplan–Meier curves between expression levels of cancer-associated fibroblasts and M2 macrophage markers (individually) and disease-
free survival in colorectal cancer patients.
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